Absorb BVS与第二代DES中期结局：系统综述与荟萃分析

数据集获取（Figshare）

• 源站标题：Mid-term outcomes of the Absorb BVS versus second-generation DES: A systematic review and meta-analysis
• DOI：10.1371/journal.pone.0197119
• 发布日期：2018-05-09
• 文件数：13 个
• 文件总体积：3.03 MB
• 源站页面：https://plos.figshare.com/articles/dataset/Mid-term_outcomes_of_the_Absorb_BVS_versus_second-generation_DES_A_systematic_review_and_meta-analysis/6241238

命令行下载

curl -L -o "pone.0197119.s001.docx" "https://ndownloader.figshare.com/files/11405198"
curl -L -o "pone.0197119.s002.docx" "https://ndownloader.figshare.com/files/11405201"
curl -L -o "pone.0197119.s003.docx" "https://ndownloader.figshare.com/files/11405210"
curl -L -o "pone.0197119.s004.docx" "https://ndownloader.figshare.com/files/11405222"
curl -L -o "pone.0197119.s005.docx" "https://ndownloader.figshare.com/files/11405225"
curl -L -o "pone.0197119.s006.docx" "https://ndownloader.figshare.com/files/11405231"
curl -L -o "pone.0197119.s007.docx" "https://ndownloader.figshare.com/files/11405234"
curl -L -o "pone.0197119.s008.docx" "https://ndownloader.figshare.com/files/11405237"

文件清单

• pone.0197119.s001.docx（130.67 KB）
• pone.0197119.s002.docx（411.07 KB）
• pone.0197119.s003.docx（359.35 KB）
• pone.0197119.s004.docx（364.90 KB）
• pone.0197119.s005.docx（378.44 KB）
• pone.0197119.s006.docx（384.06 KB）
• pone.0197119.s007.docx（366.18 KB）
• pone.0197119.s008.docx（548.41 KB）
• pone.0197119.s009.docx（13.96 KB）
• pone.0197119.s010.docx（21.98 KB）
• pone.0197119.s011.docx（16.13 KB）
• pone.0197119.s012.docx（14.86 KB）
• pone.0197119.s013.docx（17.02 KB）

文件总体积 3.03 MB（源站 API 实测）。

数据说明

Background
Bioresorbable Vascular Scaffolds (BVS) were introduced to overcome some of the limitations of drug-eluting stent (DES) for PCI. Data regarding the clinical outcomes of the BVS versus DES beyond 2 years are emerging.
Objective
To study mid-term outcomes.
Methods
We searched online databases (PubMed/Medline, Embase, CENTRAL), several websites, meeting presentations and scientific session abstracts until August 8th, 2017 for studies comparing Absorb BVS with second-generation DES. The primary outcome was target lesion failure (TLF). Secondary outcomes were all-cause mortality, myocardial infarction, target lesion revascularization (TLR) and definite/probable device thrombosis. Odds ratios (ORs) with 95% confidence intervals (CIs) were derived using a random effects model.
Results
Ten studies, seven randomized controlled trials and three propensity-matched observational studies, with a total of 7320 patients (BVS n = 4007; DES n = 3313) and a median follow-up duration of 30.5 months, were included. Risk of TLF was increased for BVS-treated patients (OR 1.34 [95% CI: 1.12–1.60], p = 0.001, I2 = 0%). This was also the case for all myocardial infarction (1.58 [95% CI: 1.27–1.96], p2 = 0%), TLR (1.48 [95% CI: 1.19–1.85], p2 = 0%) and definite/probable device thrombosis (of 2.82 (95% CI: 1.86–3.89], p2 = 40.3%). This did not result in a difference in all-cause mortality (0.78 [95% CI: 0.58–1.04], p = 0.09, I2 = 0%). OR for very late (>1 year) device thrombosis was 6.10 [95% CI: 1.40–26.65], p = 0.02).
Conclusion
At mid-term follow-up, BVS was associated with an increased risk of TLF, MI, TLR and definite/probable device thrombosis, but this did not result in an increased risk of all-cause mortality.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.1371/journal.pone.0197119（source: https://plos.figshare.com/articles/dataset/Mid-term_outcomes_of_the_Absorb_BVS_versus_second-generation_DES_A_systematic_review_and_meta-analysis/6241238）。